Nyrada Inc - Annual Report 2021

Annual Report FY21 57 17. Share-based payments (continued) The Company has calculated the fair values of the options granted using the same Black-Scholes model. For the options granted during the current financial year, the valuation model inputs used to determine the fair value at the grant date are as follows: Grant date Expiry date Assumed exercise price Expected volatility Dividend yield Risk-free interest rate 18/01/2021 15/02/2021 0.26 89.6% - 0.37% 18/01/2021 18/01/2024 0.23 1 82.6% - 0.37% 18/01/2021 18/01/2025 0.23 1 82.6% - 0.37% 18/01/2021 18/01/2026 0.23 1 82.6% - 0.37% 24/02/2021 3 years from vesting date 0.38 1 90.8% - 0.48% 29/06/2021 29/06/2026 0.40 78.0% - 0.70% 29/06/2021 29/06/2026 0.60 78.0% - 0.70% 29/06/2021 29/06/2026 0.90 78.0% - 0.70% 1 The Exercise price included in the table above is for calculation purposes only. The Exercise price will be calculated by the higher of • 100% of the Fair Market Value (as defined in the Company’s Stock Incentive Plan) of the Shares on the date that Option is granted; and • amount equal to 120% of the volume weighted average price of the CDIs for the period of 10 trading days immediately prior to the date on which that Option vests. 18. Loss per share 2021 2020 $ $ Loss after income tax attributable to the owners of Nyrada Inc. (3,539,253) (5,773,667) 2021 2020 Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 116,743,748 60,911,038 Weighted average number of ordinary shares used in calculating diluted earnings per share 116,743,748 60,911,038 2021 2020 $ $ Basic loss per share (0.03) (0.09) Diluted loss per share (0.03) (0.09) There are 16,000,000 of options which have vested and are considered to be dilutive. The options are not included as the Consolidated Entity is loss-making, so incorporating in the impacts of contingent equity is anti-dilutive.